A. Horsley (Manchester, United Kingdom), M. Stahl (Heidelberg, Germany)
Factors affecting progression of lung disease among patients with cystic fibrosis
E. Hatziagorou (Thessaloniki, Greece), C. Mantsiou (Thessaloniki, Greece), I. Lialias (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), L. Nousia (Thessaloniki, Greece), V. Avramidou (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece)
|   |
Symptom duration and the lung clearance index in children with cystic fibrosis and pulmonary exacerbations
L. Perrem (Toronto, Canada), S. Stanojevic (Toronto, Canada), M. Klingel (Toronto, Canada), S. Isaac (Toronto, Canada), R. Jensen (Toronto, Canada), M. Solomon (Toronto, Canada), H. Grasemann (Toronto, Canada), V. Waters (Toronto, Canada), N. Sweezey (Toronto, Canada), S. Davis (Chapel Hill, United States of America), F. Ratjen (Toronto, Canada)
| |
The effect of age on ventilation inhomogeneity deterioration during pulmonary exacerbations among patients with CF
E. Hatziagorou (Thessaloniki, Greece), C. Mantsiou (Thessaloniki, Greece), I. Lialias (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), L. Nousia (Thessaloniki, Greece), V. Avramidou (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece)
| |
The potential of closed circuit lung clearance index (LCI) to provide longitudinal clinical utility in cystic fibrosis (CF).
A. Horsley (Manchester, United Kingdom), A. Alrumuh (Stoke, United Kingdom), K. Bayfield (Manchester, United Kingdom), B. Bianco (Manchester, United Kingdom), S. Cunningham (Edinburgh, United Kingdom), A. Jones (Manchester, United Kingdom), A. Maitra (Manchester, United Kingdom), A. Pandyan (Stoke, United Kingdom), N. Rao (Manchester, United Kingdom), J. Tomlinson (Stoke, United Kingdom), F. Gilchrist (Stoke, United Kingdom), C. Fullwood (Manchester, United Kingdom)
| |
Inter-reader variation in lung segmentation of functional lung MRI quantification.
C. Willers (Bern, Switzerland), O. Pusterla (Basel, Switzerland), G. Bauman (Basel, Switzerland), S. Andermatt (Basel, Switzerland), S. Nyilas (Bern, Switzerland), F. Santini (Basel, Switzerland), S. Pezold (Basel, Switzerland), R. Sandkühler (Basel, Switzerland), K. Ramsey (Bern, Switzerland), P. Cattin (Basel, Switzerland), O. Bieri (Basel, Switzerland), P. Latzin (Bern, Switzerland)
| |
Clinical applicability of 3He and 129Xe ventilation MRI in cystic fibrosis: longitudinal follow up
L. Smith (Sheffield, United Kingdom), G. Collier (Sheffield, United Kingdom), H. Marshall (Sheffield, United Kingdom), P. Hughes (Sheffield, United Kingdom), A. Biancardi (Sheffield, United Kingdom), G. Norquay (Sheffield, United Kingdom), J. Bray (Sheffield, United Kingdom), O. Rodgers (Sheffield, United Kingdom), M. Wildman (Sheffield, United Kingdom), N. West (Sheffield, United Kingdom), A. Horsley (Manchester, United Kingdom), J. Wild (Sheffield, United Kingdom)
| |
Is impulse oscillometry (IOS) better than spirometry for monitoring treatment outcomes in adult cystic fibrosis (CF) pulmonary exacerbations? A pilot study
S. Lee (Adelaide, Australia), J. Morton (Adelaide, Australia), S. Chapman (Adelaide, Australia), E. Hopkins (Adelaide, Australia), C. Holmes-Liew (Adelaide, Australia), L. Bussell (Adelaide, Australia)
| |
Adult Cystic Fibrosis (CF) patients prefer to perform impulse oscillometry (IOS) in comparison to spirometry.
S. Lee (Adelaide, Australia), L. Bussell (Adelaide, Australia), S. Chapman (Adelaide, Australia), E. Hopkins (Adelaide, Australia), J. Morton (Adelaide, Australia)
| |
Use of NIV in cystic fibrosis: 10-year experience of a large adult CF centre
G. Spoletini (Leeds, United Kingdom), R. Watson (Leeds, United Kingdom), K. Pollard (Leeds, United Kingdom), C. Etherington (Leeds, United Kingdom), I. Clifton (Leeds, United Kingdom), P. Whitaker (Leeds, United Kingdom), D. Peckham (Leeds, United Kingdom)
| |
Outcomes at 6 months following NIV in adults with cystic fibrosis (CF): experience of a large UK centre
G. Spoletini (Leeds, United Kingdom), K. Pollard (Leeds, United Kingdom), R. Watson (Leeds, United Kingdom), C. Etherington (Leeds, United Kingdom), I. Clifton (Leeds, United Kingdom), P. Whitaker (Leeds, United Kingdom), D. Peckham (Leeds, United Kingdom)
| |
Observational study of sleep-related breathing disorders and preventive non-invasive ventilation in cystic fibrosis
G. Parisi (Catania, Italy), M. Papale (Catania, Italy), S. Manti (Messina, Italy), E. Mulè (Catania, Italy), N. Rotolo (Catania, Italy), S. Leonardi (Catania, Italy)
| |
Assessment of activity tracker wear-time in longitudinal measurement of physical activity in children and young people with CF
H. Douglas (London, United Kingdom), E. Raywood (London, United Kingdom), K. Kapoor (London, United Kingdom), G. Saul (Cambridge, United Kingdom), T. Kuzhagaliyev (London, United Kingdom), M. Bryon (London, United Kingdom), L. Stott (Cambridge, United Kingdom), E. Main (London, United Kingdom)
| |
Different methods of measuring physical activity in cystic fibrosis: accelerometer versus new electronic devices
D. Savi (Rome, Italy), L. Graziano (Rome, Italy), S. Schiavetto (Rome, Italy), N. Simmonds (London, United Kingdom), B. Giordani (Rome, Italy), E. Leggieri (Rome, Italy), M. Rivolta (Rome, Italy), D. Asciutti (Rome, Italy), P. Palange (Rome, Italy), J. Elborn (London, United Kingdom)
| |
Determining resting heart rate in children using wearable activity monitors
K. Kapoor (London, United Kingdom), E. Raywood (London, United Kingdom), H. Douglas (London, United Kingdom), G. Saul (London, United Kingdom), N. Correvon (London, United Kingdom), T. Kuzhagaliyev (London, United Kingdom), L. Stott (London, United Kingdom), E. Main (London, United Kingdom)
| |
Does cystic fibrosis impact skeletal muscles and diaphragm function?
N. Uslu (Istanbul, Turkey), D. Kocakaya (Istanbul, Turkey), S. Olgun Yildizeli (Istanbul, Turkey), E. Eryüksel (Istanbul, Turkey), Ö. Kenis Coskun (Istanbul, Turkey), C. Cimsit (Istanbul, Turkey), S. Görçin Karaketir (Istanbul, Turkey), B. Ceyhan (Istanbul, Turkey)
| |
Does an individualized long-term exercise training program affect the cardiorespiratory capacity and cardiac function in young patients with cystic fibrosis?
E. Hatziagorou (Thessaloniki, Greece), S. Giannakoulakos (Thessaloniki, Greece), E. Kouidi (Thessaloniki, Greece), M. Anifanti (Thessaloniki, Greece), C. Mantsiou (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), L. Nousia (Thessaloniki, Greece), A. Kampouras (Thessaloniki, Greece), A. Deligiannis (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece)
| |
Regular routine SF6 multiple breath washout in infants with cystic fibrosis born after implementation of neonatal screening
R. Sandvik (Copenhagen, Denmark), M. Schmidt (Copenhagen, Denmark), T. Pressler (Copenhagen, Denmark), C. Voldby (Copenhagen, Denmark), F. Buchvald (Copenhagen, Denmark), P. Gustafsson (Skövde, Sweden), M. Skov (Copenhagen, Denmark), K. Nielsen (Copenhagen, Denmark)
| |
Arterial partial pressure of oxygen (PaO2) - a marker for cystic fibrosis (CF) lung disease and chronic airway infection
R. Gaupmann (Vienna, Austria), S. Gruber (Vienna, Austria), L. Gona-Hoepler (Vienna, Austria), E. Nachbaur (Vienna, Austria), Z. Szepfalusi (Vienna, Austria), S. Renner (Vienna, Austria), E. Dehlink (Vienna, Austria)
| |